You must be a subscriber to see the full results of your search.
Please log in or subscribe below if you are not already a subscriber.
The Daily News subscribers get full access to more than
million names and addresses along with powerful search and download features.
Get the business leads you need with powerful searches of public records and notices.
Download listings into your spreadsheet or database.
Learn more about our services
| Search again
Editorial Results (free)
1. Mylan, Like Other Generic Drugmakers, Feels the Pricing Pain
- Thursday, August 10, 2017
NEW YORK (AP) – Mylan's second-quarter profit and revenue surged, but not as much as Wall Street had expected and the company is taking a more conservative view going forward because of "ongoing challenges and the uncertain U.S. regulatory environment."
2. High Court Ruling Speeds Up Generic Biotech Drug Approval
- Tuesday, June 13, 2017
WASHINGTON (AP) – A unanimous Supreme Court is speeding up the time for generic biotech drugs to become available to the public in a ruling that means a loss of billions in sales to the makers of original versions.
3. Justices Hear Dispute Over Lower-Cost Biotech Drugs Sales
- Thursday, April 27, 2017
WASHINGTON (AP) – The Supreme Court on Wednesday considered a drug company's fight to keep a generic version of its biotech drug off the market for an additional six months that would mean billions more in sales and higher costs to the public.
4. Supreme Court Weighs Generic Drug Dispute
- Thursday, October 16, 2014
WASHINGTON (AP) – The Supreme Court seems divided as it considers a high-stakes patent dispute between rival pharmaceutical companies over the world's best-selling multiple sclerosis treatment.
5. Supreme Court Takes Up Drug Company Dispute
- Tuesday, April 1, 2014
WASHINGTON (AP) – The Supreme Court is wading into a patent dispute between rival pharmaceutical companies over a multiple sclerosis treatment.
The justices agreed Monday to hear an appeal from Teva Pharmaceutical Industries Ltd., which claims the U.S. Court of Appeals for the Federal Circuit wrongly overturned five of its patents for the drug Copaxone.
6. FDA: New Suppliers to Ease 2 Cancer Drug Shortages
- Wednesday, February 22, 2012
TRENTON, N.J. (AP) – Federal regulators have approved new suppliers for two crucial cancer drugs, easing critical shortages that had been ratcheting up fears that patients, particularly children with leukemia, would miss lifesaving treatments.